1) to examine the reporting of outcome measures in orthopaedic trials, 2) to determine the feasibility of blinding in published orthopaedic trials and 3) to examine the association between the magnitude of treatment differences and methodological safeguards such as blinding. Specifically, we focused on an association between blinding of outcome assessment and the size of the reported treatment effect; in other words: does blinding of outcome assessors matter?
1) the outcome measures used and 2) the use of a methodological safeguard: blinding. We calculated the magnitude of treatment effect of blinded compared to un-blinded outcome assessors.
1) studies labelled as Level I have high reporting quality and 2) Level I studies have better reporting quality than Level II studies. One should address methodological safeguards individually.
1) younger age, particularly age between 36 and 45 years, 2) experience of less than 10 years, 3) having a PhD degree, and 4) working in an academic or teaching setting. The majority of the respondents (65%) were aware of the Journal’s evidence-based medicine section, and 20% used the Journal’s evidence-based medicine abstracts in clinical decision-making. This increased awareness in evidence-based medicine was also reflected in a frequent use of Cochrane reviews in clinical decision-making (27%). Surgeons who used the Journal’s evidence-based medicine abstracts and Cochrane reviews had significantly higher competence scores.